

1 **Full Title:** Inflammatory cytokines and a diverse cervicovaginal microbiome are associated with
2 cervical disease in Hispanics living in Puerto Rico

3 **Short Title:** bacterial diversity and cervical cancer in Puerto Rico

4 Eduardo Tosado-Rodríguez¹, Loyda B. Mendez², Ana M. Espino¹, Stephanie Dorta-Estremera^{1,3},

5 Edna E. Aquino¹, Josefina Romaguera⁴ and Filipa Godoy-Vitorino^{1*}

6

7 ¹ Department of Microbiology and Medical Zoology, School of Medicine, Medical Sciences
8 Campus, University of Puerto Rico, USA

9 ² University Ana G. Méndez, Carolina Campus, Carolina, Puerto Rico, USA

10 ³ Cancer Biology, Comprehensive Cancer Center University of Puerto Rico, USA

11 ⁴ Department of OBGYN, School of Medicine, Medical Sciences Campus, University of Puerto
12 Rico, USA

13

14 * Corresponding author

15 Filipa Godoy-Vitorino, Ph.D.

16 filipa.godoy@upr.edu

17

18 **Keywords:** Cervicovaginal microbiota, Cytokines, 16S rRNA, Hispanics, inflammation

19

20

21 Abstract

22 Cervical cancer (CC) is women's fourth most common cancer worldwide. A worrying increase in
23 CC rates in Hispanics suggests that besides Human Papillomaviruses infections, there may be other
24 biological causes promoting the disease. We hypothesized that the cervical microbiome and the
25 epithelial microenvironment favoring inflammation is conducive to disease progression. There is
26 a lack of studies examining the part played by microbial populations in the development of
27 precancerous lesions into cancer in Hispanic women. We aimed to investigate the relationship
28 between the cervicovaginal microbiome and inflammation in Hispanic women living in PR while
29 considering cervical neoplasia and HPV infection. Cervical samples collected from 91 participants
30 coming to clinics in San Juan, underwent 16S rRNA genes (V4 region) profiling, and cytokines
31 were measured using Luminex MAGPIX technology. Cytokines were grouped as inflammatory
32 (IL-1 β , TNF α , IFN γ , IL-6), anti-inflammatory (IL-4, IL-10, TGF β 1), and traffic-associated (IL-
33 8, MIP1a, MCP1, IP10). They were related to microbes via an inflammation scoring index based
34 on the quartile and tercile distribution of the cytokine's concentration. We found significant
35 differences in the diversity and composition of the microbiota according to HPV risk, cervical
36 disease, and cytokine abundance. The most dominant community state type (CST) was CST IV
37 with ~ 90% dominance in participants with high-grade squamous intraepithelial lesions and high-
38 risk HPV. The increasing concentration of pro-inflammatory cytokines was associated with a
39 decrease in *L. crispatus*. In contrast, dysbiosis-associated bacteria such as *Gardnerella*, *Prevotella*,
40 *Atopobium* concomitantly increased with pro-inflammatory cytokines. Our study highlights that
41 the cervical microbiota of Hispanics living in PR is characteristically diverse, regardless of HPV
42 status and that dysbiosis associated with a decrease in *Lactobacillus* marks inflammatory

43 processes. Therefore, the joint host-microbe interaction analyses via cytokine signaling and
44 microbiota in precancerous lesions is confirmed to have great translational potential.

45

46 Introduction

47 Cervical cancer (CC) is the 4th most common cancer among women and the 4th leading cause of
48 cancer death in females worldwide (Cohen et al. 2019). Although CC rates have decreased in the
49 USA (Chatterjee et al. 2016), the incidence and mortality from cervical cancer mainly occurs in
50 low resource settings (~ >85%) (Ferlay et al. 2010). According to the Pan American Health
51 Organization for 2012, 80% of American deaths due to CC occur in Latin America and the
52 Caribbean (1). Puerto Rico (PR) has the highest age-adjusted incidence of CC in the US (Ortiz et
53 al. 2010), with notably higher incidence from 2001 to 2017, increasing from 9.2 to 13 per 100,000
54 person-years (Ortiz et al. 2021). PR also has a 79.3% CC screening rate that does not achieve
55 CDC's screening recommendations of 93% (Centers for Disease and Prevention 2012; Ortiz et al.
56 2010) posing a strain on health systems in the island (2).

57 Persistent infection with oncogenic Human Papillomavirus (HPV) is the most important cause of
58 CC. HPV infections range from 90–100% prevalence in cervical abnormalities, from high-grade
59 squamous intraepithelial lesion -HSIL- to severe dysplasia and cancer (3), where the viral
60 genome integration modulates the host cell cycle promoting neoplasia progression (4,5). However,
61 other factors influence cervical disease progression, including lifestyle, genetic predisposition,
62 immunosuppression, early onset of sexual activities, and many pregnancies and deliveries (6–8).
63 Nevertheless, why only a fraction of women acquires a long-lasting, persistent high-risk HPV (HR-
64 HPV) that puts them at risk for developing Cervical Intraepithelial Neoplasia (CIN) remains

65 unknown. One potential explanation for this variation could be the cervicovaginal microbiota and
66 its related processes. Recent studies suggest an association between certain bacterial community
67 types of the vaginal microbiota, HPV infection, and cervical disease (9–11). Additionally,
68 processes like bacterial vaginosis, cervical inflammation, and increased vaginal pH are all known
69 to affect susceptibility to cervical HPV (12).

70 Women of different ethnic groups differ in their vaginal microbiome signatures (13). The
71 cervicovaginal microbiome has been characterized into five different community state types (CST)
72 according to the dominance of *Lactobacillus* species, a concept that was introduced in 2011 by
73 Ravel et al. to categorize vaginal microbial communities among reproductive-age women (13).
74 CST-I refers to communities dominated by *L. crispatus* (CST-I), CST-II by *L. gasseri*, CST-III
75 by *L. iners*, CST-V by *L. jensenii* (CST-V), or non-*Lactobacillus* dominated and highly diverse
76 profiles such as CST-IV. Furthermore, CST-IV is often characterized by three sub-CSTs: 1) CST
77 IV-A has a high relative abundance of *Candidatus Lachnocurva vaginae* and a moderate relative
78 abundance of *G. vaginalis* and *Atopobium vaginae*, 2) CST IV-B also has a moderate relative
79 abundance of *G. vaginalis* and *Atopobium vaginae*, while 3) CST IV-C has low relative abundance
80 of *Lactobacillus* spp., as well as low levels of *G. vaginalis*, *A. vaginae*, and *Ca. L. vaginae* with
81 high facultative and strictly anaerobic bacteria (14). While *Lactobacillus* dominates the
82 cervicovaginal microbiome of Caucasians, Hispanic and black women have higher diversity and
83 reduced *Lactobacillus* populations (13). A previous study demonstrated that Hispanics living in
84 PR have a different microbial profile than Caucasians, and that patients with high-risk HPV and
85 CIN3 cervical lesions had dominant *Atopobium vaginae* and *Gardnerella vaginalis* (11,15).
86 However, these results could have been improved, as they identified microbiota using cervical
87 swabs, failing to address the host response. Recent studies have highlighted the benefit of

88 collecting cervical lavages to understand the extent of the dynamic host-microbe symbioses via
89 proteomic, metabolomic, or cytokine profiling analyses (16–19).

90 We hypothesized that there would be changes in the cervical microenvironment with cervical
91 disease and HPV risk and that markers of inflammation would be associated with a decrease in
92 *Lactobacillus* and overall dysbiosis. To test this hypothesis, we investigated the relationship
93 between the cervicovaginal microbiome with cervical neoplasia and HPV infections and
94 characterized the host immune profiles through profiling cytokine expression analyses from
95 cervical lavages.

96 This study provides insight into specific bacterial taxonomic changes promoting a pro-
97 inflammatory state associated with cervical dysplasia and represents the first effort to combine
98 microbiome and cytokine profiling in Hispanics living in Puerto Rico.

99

100 Materials and Methods

101 Participant Recruitment and Sample Collection

102 Women coming for routine medical care to the University of Puerto Rico and San Juan City clinics
103 (San Juan Metropolitan area), were recruited as part of IRB protocol 1050114 with IBC protocol
104 94620. Only women who did not meet the exclusion criteria were recruited and evaluated.
105 Exclusion criteria included: 1) Active urinary infections, 2) history of common urinary
106 incontinence, 3) sexually transmitted diseases (STDs), 4) antibiotics taken in the prior month, 5)
107 candidiasis, and 6) treatment for or suspicion of prior toxic shock syndrome. All subjects were
108 informed of the study's sampling procedure, risks, and benefits with written informed consent and

109 a verbal explanation of the document. A detailed questionnaire from which some of the metadata
110 variables were collected was administered. All procedures were done according to the Declaration
111 of Helsinki. The date range in which human subjects' data/samples were collected was between
112 November 2017 and February 2020. The study and its procedures were conducted from March
113 2020 and October 2022.

114 A total of 91 women, 21-60 years old and able to provide informed consent, were enrolled in our
115 study. Cervical samples were collected through speculum access during the gynecological
116 examination by using cotton tip collection swabs. Sterile Catch-All Specimen Collection Swabs
117 (Epicentre Biotechnologies, Madison WI, United States) were placed in the cervix, rotated along
118 the lumen with a circular motion, and then placed in sterile 2 milliliters (mL) microtubes with cap.
119 We collected approximately 10mL of cervical lavages (CVL) by injecting pure certified nuclease-
120 free water (Growcells, Irvine, CA) into the vaginal canal. Collected lavages were stored in a clean
121 15mL collection tube and pH was measured with hydriion wide range pH paper strips (Merck,
122 Germany). All samples were stored at -80°C and processed for nucleic acid extraction and
123 cytokine profiling at our UPR School of Medicine laboratory to reduce processing variation.

124

125 Cytokine Detection and Measurement with Bio-Plex Immunoassay 126 System

127 A total of 91 cervical lavages were tested in duplicate with a multiplex solid-based immunoassay
128 (Bio-Plex Pro Human Cytokine 10-plex Assay, Bio-Rad) using the same volume of CVL across
129 samples (80 uL) for the Luminex MAGPIX® system. Cytokines/chemokines analyzed were IL-
130 1β , IL-4, IL-6, IL-8, IL-10, TNF- α , IFN γ , IP10, MIP1, and MCP1. Also, 91 samples were tested

131 in duplicate using Bio-Plex Pro TGF- β 3-plex immunoassay (BioRad, Hercules, CA, USA). We
132 performed all analyses following the manufacturer's recommendations.

133

134 Cytokine/Chemokine Profile Analyses

135 Data were analyzed with the Bio-Plex Manager 6.1 software (BIO-RAD, Hercules, CA) using a
136 5-parameter logistic curve that was verified for normality before statistical testing (20).
137 Inflammation scores were assigned to each cytokine/chemokine for each sample using Fluorescent
138 Intensity (FI) results. Scores were calculated by distributing samples across statistical quartiles or
139 tertiles. If a sample was within the first quartile, a score of 1 was assigned, that is for all other three
140 quartiles (score 1 < 0.25 < score 2 < 0.50 < score 3 < 0.75 < score 4 < 1). TGF- β scores were
141 calculated using tertiles with scoring categories including: score 1 < 0.33, score 2 from 0.33 to
142 0.66 and score 3 < 1. Cytokines were grouped according to their function on host physiology,
143 including: pro-inflammatory (IL-1 β , TNF- α , IFN γ , IL-6), anti-inflammatory (IL-4, IL-10, TGF β 1)
144 and traffic-associated cytokines(IL-8, MIP1a, MCP1, IP10) (21,22). With the scoring in either
145 tertiles or quartiles, we also created a categorical variable, to which scores of 2 or 1 corresponded
146 to low levels of cytokines and > 2 high levels. These ranked score assignments using the
147 distribution of cytokines were directly related to the concentration (fluorescence intensity) of
148 cytokines/chemokines in a sample. Therefore, we used them to combine microbial community
149 analysis (16S rDNA profiles) with inflammation scores as a metadata variable (see methods
150 section "Statistical Analyses of the Microbiota Profiles" for more details). This combination
151 allowed us to detect specific taxa associated with altered cytokine profiles. For comparisons
152 between multiple groups, we used ANOVA, and for comparisons between two groups, we used
153 the student's *t*-test. All statistical analyses were done using GraphPad Prism 6.0 (San Diego, CA).

154

155 DNA Extraction and 16S rDNA Sequencing

156 Genomic DNA extractions from swabs were performed with the Qiagen Power Soil Kit (QIAGEN
157 LLC, Germantown Road, Maryland, USA) following an optimized protocol for these types of
158 samples as described in a previous study (11). DNA was quantified with a Qubit® dsDNA HS
159 (High Sensitivity) Assay (Waltham, Massachusetts, US) (ranging from 5-100ng/μL). An average
160 of 10-30ng/μL genomic DNA was shipped to an outsourced sequencing facility.

161 DNA from cervical samples was normalized to 4nM during 16S library prep. The V4
162 hypervariable region of the 16S ribosomal RNA marker gene (~291bp) was amplified using
163 universal bacterial primers: 515F (5'GTGCCAGCMGCCGCGGTAA3') and 806R
164 (5'GGACTACHVGGGTWTCTAAT3') as in the Earth Microbiome Project
165 (<http://www.earthmicrobiome.org/emp-standard-protocols/16s/>) (23). The 16S-rRNA reads and
166 corresponding sample metadata was deposited in QIITA study ID 12871 (24), and the raw
167 sequences are available in the European Nucleotide Archive ENA Project under accession number
168 EBI: ERP136546.

169

170 HPV Genotyping process

171 We used a kit based on a highly sensitive short-polymerase chain reaction-fragment assay (Labo
172 Biomedical Products, Rijswijk, The Netherlands, licensed Innogenetics technology). It uses SPF10
173 primers to amplify a 65-bp fragment of the L1 open reading frame of HPV genotypes, followed
174 by a Reverse-Hybridization step to determine which HPV type is present by comparing to kit-
175 provided controls. This assay allows for the identification of the following common mucosal HPV
176 genotypes: 14 High-risk types including (HPV 16, 18, 31, 33, 35, 39,45, 51, 52, 56, 58, 59, 66

177 and 68/73) and 11 Low-risk types (6, 11, 34, 40,42, 43, 44, 53, 54,70, 74). Previous studies explain
178 the method in detail (Vargas-Robles et al. 2018)Godoy-Vitorino et al. 2018).

179

180 Quality Control and Sequence Processing

181 Raw read pre-processing of demultiplexed files was done with a Phred offset of 33 and default
182 parameters using split libraries FASTQ (QIIMEq2 1.9.1) in QIITA (24). Sequences were trimmed
183 to 250 bp, followed by the deblurring workflow (deblur 1.1.0) (24,25). For taxonomy assignment
184 we used a modified Greengenes reference database (Greengenes_13.8) (26,27) with a minimum
185 similarity threshold of 97%. The species table was downloaded for downstream analyses using a
186 locally run version of QIIME (28). Singletons, amplicon sequence variants (ASVs) with less than
187 three reads, and sequences matching chloroplasts, mitochondria, and taxonomically unassigned
188 sequences were removed from downstream analyses. All samples were rarefied to 7400 reads per
189 sample.

190

191 Vaginal Community State Type Nearest Centroid Classifier 192 (VALENCIA)

193 The taxonomy of cervical microbial communities was sorted into categories termed community
194 state types (CSTs). This categorization collapses a taxonomic profile into a single categorical
195 variable, allowing data exploration and statistical modeling (14). In addition, categorization allows
196 unbiased analysis of small and sizable vaginal microbiota datasets, comparisons between datasets,
197 and meta-analyses that combine multiple datasets. We used the data package at github.com/ravel-

198 lab/VALENCIA to analyze the following standard parameters and categorize our cervicovaginal
199 communities into different CST and sub-CST categories (14).

200

201 Analyses of Microbial Community Structure and Diversity

202 For community-level analyses, we computed the pairwise Bray-Curtis distances (Beta diversity)
203 which quantify the compositional dissimilarity between samples (29). We visualized bacterial
204 community composition and structure differences using non-metric multidimensional scaling
205 (NMDS). Alpha diversity measure of Chao1 (richness), and Shannon index (30) (diversity) were
206 computed and plotted using R with packages: “phyloseq”, “vegan” and “ggplot2” (31–33). Bar
207 Plots showing genus and species-level taxa were computed using a locally run version of QIIME2
208 (28).

209 The metadata variables included in our study were: 1) cervical disease, defined as the cytological
210 phenotype of negative for intraepithelial lesion or malignancy (NILM), low-grade squamous
211 intraepithelial lesion (LGSIL) and high-grade squamous intraepithelial lesion (HGSIL); 2) HPV
212 risk, defined as HPV negative, HPV positive with co-infection (low and high-risk HPV
213 simultaneously), and HPV positive high-risk (exclusively high-risk types); 3) cytokine ranks
214 (estimated through quartile and tertile distribution of the fluorescence scores as detected by
215 Luminex MAGPIX® system); and 4) community state types (CSTs).

216

217 Statistical Analyses of the Microbiota Profiles

218 For beta diversity analyses, we tested if distances between sample groups were statistically
219 significant using ANOSIM, a non-parametric statistical test (34). Using a Bray-Curtis distance

220 table, we used this test to compare ranked beta diversity distances between the different variables.
221 These tests were done using the script "qiime diversity beta-group-significance" for each specific
222 test in QIIME2 (28) with the distance matrix as the input file and 999 permutations (34). Statistical
223 analyses for alpha diversity were done using the script "qiime diversity alpha-group-significance"
224 in QIIME2 (28), which uses a non-parametric t-test with Monte Carlo permutations. Additionally,
225 to ascertain if there are statistically significant differences between the ASV abundance in the
226 different sample groups, we used linear discriminant analysis (LDA) effect size (LEfSe) (35)
227 through R, using MicrobiomeAnalyst (36). Significant ASVs were determined considering a p-
228 value of < 0.05 and LDA scores of 1.5 for all cytokine groups. Cytokine fluorescence values (as
229 logarithms) were associated to differentially abundant levels of *L. crispatus*, *L. iners*, *Sneathia*,
230 *Gardnerella*, *Atopobium* and *Prevotella* using a linear mixed model (LMM) in R (ggplot and
231 reshape2 libraries), correcting for age and body mass index (BMI). Differential abundance analysis
232 was performed using amplicon sequence variants corresponding to *L. crispatus*, *L. iners*, *Sneathia*,
233 *Atopobium*, *Gardnerella* and *Prevotella*. They were evaluated for their differential presence across
234 the cytokine groups. Initially, a summary of each one of the ASVs of interest was used to perform
235 groupings due to abundance. The groupings were separated as follows ASV 0-50 counts = very
236 low abundance; ASV count 51-500 = low abundance; and >500 = high abundance.

237

238 Results

239 Population description and Community State Types (CSTs) prevalence

240 A total of 91 women were included in the study. The mean age was 39 years old. Women had an
241 average pH value of 5.49. The distribution of the groups of samples according to cervical neoplasia

242 severity included Negative for Intraepithelial Lesion or Malignancy (NILM) (N=56) Low-Grade
243 Squamous Intraepithelial Lesion (LGSIL) (N=18), and High Grade Squamous Intraepithelial
244 Lesion (HGSIL) (N=17), with differential HPV status and cytokine ranks (Table 1, S1 Table).
245 HPV infections had a prevalence of 67.0% (including infections with any HPV type) with a higher
246 prevalence of HPV+ among women with LGSIL (94.4%) and HSIL lesions (88.2%) (Table 1). As
247 expected, HR-HPV prevalence was higher in HGSIL (82.4%) compared to in LGSIL (50.0%) and
248 negative cervical lesions (39.3%) (p=0.015). Participants with HPV co-infection were primarily
249 observed in participants with low-grade lesions (44.4%) (p=0.040), and less abundant in the group
250 with high-grade lesions (5.9%). There were no significant differences in the distribution of the
251 BMI groups across cervical disease, with equal proportions of normal weight, overweight and
252 obese women (Table1). Across all women, cervical lesion prevalence was 38.5% (including
253 LGSIL and HGSIL), Individually, LGSIL and HGSIL comprised 19.8% and 18.7% of the samples,
254 respectively. CST1 mainly was present in 16% of the NILM cases and 22% LGSIL while not being
255 present in HGSIL. In contrast, CST IV-B was only identified on participants with high-grade
256 lesions (HGSIL) (p=0.025) (Table 1). Prevalence analysis of CSTs per levels (high and low) of
257 cytokine groups (pro-inflammatory, traffic-associated, and anti-inflammatory) revealed that CST
258 IV-C is the more prevalent in all cytokines (S1 Fig., S2 Table).

259 **Table 1.** Characteristics of the population.

260

	NILM	LGSIL	HGSIL	TRUE	P-value *
	(N=56)	(N=18)	(N=17)	(N=91)	
Age					
Mean (SD)	40.4 (12.0)	39.6 (9.55)	33.9 (9.47)	39.1 (11.3)	0.213

Median [Min, Max]	38.5 [21.0, 60.0]	38.5 [25.0, 56.0]	33.0 [22.0, 56.0]	37.0 [21.0, 60.0]	
BMI_Analysis					
Normal	20 (35.7%)	5 (27.8%)	7 (41.2%)	32 (35.2%)	NS
Obese	18 (32.1%)	8 (44.4%)	5 (29.4%)	31 (34.1%)	
Overweight	18 (32.1%)	4 (22.2%)	5 (29.4%)	27 (29.7%)	
Not recorded	0 (0%)	1 (5.6%)	0 (0%)	1 (1.1%)	
pH					
Mean (SD)	5.50 (0.500)	5.36 (0.413)	5.60 (0.573)	5.49 (0.500)	0.486
Median [Min, Max]	5.50 [5.00, 7.00]	5.25 [5.00, 6.00]	5.50 [5.00, 6.50]	5.50 [5.00, 7.00]	
HPV_Status					
HPV-	27 (48.2%)	1 (5.6%)	2 (11.8%)	30 (33.0%)	
HPV+	29 (51.8%)	17 (94.4%)	15 (88.2%)	61 (67.0%)	2.48EE-4
HPV_Risk					
HPV-	27 (48.2%)	1 (5.6%)	2 (11.8%)	30 (33.0%)	0.003
Co-infection	7 (12.5%)	8 (44.4%)	1 (5.9%)	16 (17.6%)	0.040
High_Risk	22 (39.3%)	9 (50.0%)	14 (82.4%)	45 (49.5%)	0.016
CST					
I	9 (16.1%)	4 (22.2%)	0 (0%)	13 (14.3%)	
IV-A	12 (21.4%)	5 (27.8%)	5 (29.4%)	22 (24.2%)	
IV-C	35 (62.5%)	9 (50.0%)	8 (47.1%)	52 (57.1%)	
IV-B	0 (0%)	0 (0%)	4 (23.5%)	4 (4.4%)	0.025

*Kruskal-Wallis test for continuous and Fisher's test for categorical variables

261

262 Cytokine changes according to high-grade lesions and community state

263 types (CSTs)

264 There were significant differences in fluorescence between pro-inflammatory cytokines IL-1 β and
265 IFN γ among women with high grade disease, compared to healthy participants. There was
266 significantly higher fluorescence values between HGSIL and (NILM / HPV- p=0.008) or with
267 participants with low-grade disease (p=0.015) (Fig. 1 A). Although there were no significant
268 differences among groups when evaluating traffic-associated cytokines (Fig. 1B) or anti-
269 inflammatory cytokines (Fig. 1C), there was a tendency for higher fluorescence levels in
270 participants with any cervical disease (LGSIL and HGSIL). Although an analysis evaluating the
271 cytokines according to HPV risk was done, no significant differences were identified (S2 Fig.).

272 Evaluation of cytokines according to CSTs revealed significant differences in IL-1 β , IL-6, MIP1a
273 and IP10 concentrations. CST IV-B was found to be associated with a significantly higher
274 concentration of IL-1 β (p=1.0EE-4), IL-6 (p=0.050) and MIP1a (p=0.008) when compared to
275 *Lactobacillus*-dominated CST I. (Fig. 2). In contrast, IP10 was significantly higher in CST I
276 compared to CST IV-A (p=0.031) (Fig. 2).

277 **Fig. 1. Cytokine Profiles grouped as pro inflammatory (A) (IL-1 β , TNF α , IFN γ , IL-6), anti-**
278 **inflammatory (B) (IL-4, IL-10, TGF β 1) and traffic-associated cytokines(C) (IL-8, MIP1a, MCP1,**
279 **IP10) cytokines evaluated through LUMINEX and plotted according to cervical disease.**
280 Fluorescence Intensity values were used to compute multiple comparison analysis using ordinary
281 one-way ANOVA with Tukey's multiple comparisons test. Results were depicted in boxplots for
282 cervical disease. Significant differences are highlighted by brackets and corresponding p-values.

283

284 **Fig. 2. Cytokine Profiles of IL-1 β , IL-6, MIP1a and IP10 cytokines evaluated through**
285 **LUMINEX, plotted according to CST classification.** Fluorescence Intensity values were used

286 to compute multiple comparison analyses using ordinary one-way ANOVA with Tukey's multiple
287 comparisons tests. Results are depicted in boxplots for cervical disease, and brackets and
288 corresponding p-values highlight significant differences.

289
290 **HPV infection and cervical disease are associated with altered bacterial**
291 **community composition**

292 A total of 2,067,074 good-quality 16S rRNA sequence reads and 8,167 OTUs were analyzed, with
293 a rarefaction level of 7,400 reads per sample. Our samples mainly included reproductive-age
294 women (n = 73) and women in menopause (n = 18). To evaluate whether changes in cervicovaginal
295 microbiota are associated according to the women's physiological state, we analyzed beta and
296 alpha diversity between these categories. We found no significant differences neither in beta
297 (Bray-Curtis) (S3 Fig. A) nor in alpha diversity (Shannon) (S3 Fig. B). The microbiota
298 composition did not reveal any unique taxa associated with any of the evaluated groups (S3 Fig.
299 C). Additionally, we evaluated the cytokine profiles associated to menopause state (S3 Fig. D, E
300 and F). We found no significant differences among menopause and non-menopause women
301 according to the cytokine profiles. All the associations of cytokines with specific taxa were
302 corrected for age.

303
304 **Fig. 3. Diversity analyses according to cervical disease and HPV risk categories.** Bray-Curtis
305 analysis represented by Non-metric multidimensional scaling (NMDS) using cervical disease and
306 HPV risk as metadata categories (A, D). Alpha diversity (Shannon) was calculated and depicted

307 in Figs B and E. Bar Plots depicting relative abundance of bacteria at the species level for cervical
308 disease (C) and HPV risk (F). Red asterisks mean significant differences among groups ($p < 0.05$).

309

310 We evaluated the differences in the microbiota according to cervical disease and HPV risk. Beta
311 diversity analyses considering cervical disease, revealed that bacterial community structure was
312 significantly different according to cervical disease severity (LGSIL $p = 0.026$) (HGSIL $p = 0.003$)
313 when compared to healthy controls (NILM/HPV-) (Fig. 3A). As for HPV risk, community
314 structure was found to be significantly altered due to HR-HPV infection ($p = 0.042$) and HPV co-
315 infections ($p = 0.004$) compared to HPV negative samples (Fig. 3D, S3 Table). Alpha diversity
316 (Shannon) increased concomitantly to the severity of the epithelial lesions, including significant
317 differences between NILM and HGSIL ($p = 0.003$), regardless of HPV infection (Fig. 3B, S4
318 Table). In contrast, alpha diversity increased in participants with HPV co-infections as compared
319 to HPV negatives ($p = 0.032$) (Fig. 3E, S4 Table).

320 The microbiota composition between NILM and LGSIL participants was not different and was
321 dominated by *L. crispatus* and *L. inners*. Participants with HGSIL had a change in *Lactobacillus*
322 distribution, being dominated by *L. inners* and other taxa associated with dysbiosis, such as
323 *Lachnospiraceae sp.*, *P. bivia*, *A. vaginae* and *G. vaginalis* (Fig. 3C). Bacterial composition
324 changed dramatically according to HPV Risk, favoring a predominance of *L. crispatus* in HPV
325 negative women, and *L. inners* in high-risk participants (Fig. 3F). Participants with HPV co-
326 infections had a highly diverse taxonomic profile with dysbiosis associated taxa including,
327 *Prevotella sp.*, *Megasphaera sp.*, *Sneathia*, *Aerococcus christinsenii* and *Streptococcus anginosus*
328 (Fig. 3F).

329 As identified by linear discriminant analysis (LDA) effect size (LEfSe), putative microbial
330 biomarkers detected *Parabacteroides* and *Akkermansia* in participants with HGSIL. As for HPV
331 risk, we found that *Sneathia* was more abundant in HPV-negative participants with cervical
332 disease. In addition, for HPV co-infections, we identified *Megasphaera*, *Parabacteroides*,
333 *Akkermansia* and *Bacteroides* as significantly differentiated taxa (Fig. 4).

334
335 **Fig. 4. Linear discriminant analysis (LDA) effect size (LEfSe) for cervical disease and HPV**
336 **risk at the Genus level.** Cutoff was 1.5 LDA score and a p value of 0.05. Log-level changes in
337 LDA score are displayed on the x axis.

338

339 Association of bacterial taxa with cytokine levels

340 In a balanced vaginal tract, *Lactobacillus* species impede the colonization of other bacteria that
341 would otherwise cause infections. *L. Crispatus* produce lactic acid, bacteriocins and H₂O₂ acting
342 as a chemical barrier (Valenti et al. 2018). Very low levels of *L. crispatus*, a key vaginal bacterium
343 in eubiosis, were significantly associated to high concentrations of pro-inflammatory cytokines
344 IL-1 β (p=2.16E-6) and IFN γ (p=0.013) (Fig. 5). High levels of *L. iners* were significantly
345 associated with high levels of IL-6, also a pro-inflammatory cytokine (p=0.019), suggesting that
346 this species of *Lactobacillus* might stimulate IL6 production (Fig. 5). On the contrary, low levels
347 of *L. iners* correlate with lower expression of IFN γ (p=0.039) (Fig. 5). Very low levels of
348 *Atopobium*, a mostly pathogenic bacteria were significantly associated with low levels of IL-1 β
349 (p=0.002). As for *Sneathia*, another dysbiosis associated taxa, detected at low levels, had
350 correlation with higher levels of IFN γ (p=7.00E-6), TNF α (p=7.00E-4) TNF α (p=0.010) (Fig. 5).
351 Absence, or very low levels anaerobic *Gardnerella*, were associated with lower fluorescence

352 values of IL-1 β (p=1.00E-6) (Fig. 5). Very low abundance of *Prevotella* correlated with lower
353 concentrations of IL-1 β in our samples (p=3.00E-6) (Fig. 5).

354

355 **Fig. 5. Association of key vaginal bacteria with levels of pro-inflammatory cytokines.**

356 Cytokine logarithm fluorescence values were associated to differentially abundant levels of *L.*
357 *crispatus*, *L. iners*, *Sneathia*, *Gardnerella*, *Atopobium* and *Prevotella* using a linear mixed model
358 (LMM), correcting for age and BMI. Differential abundance groupings were separated as follows
359 ASV 0-50 counts = very low abundance; ASV count 51-500 = low abundance; and >500 = high
360 abundance.

361

362 In beta diversity, axis 1 of the NMDS1 plot separated samples according to their cytokine levels
363 (S4 Fig. A, D, G). When compared to healthy controls (NILM/HPV-) we found changes in
364 microbial community structure significantly associated with high levels of pro-inflammatory
365 cytokines regardless of HPV infection (NILM/HPV-, p=0.006; NILM/HPV+, p=0.001) and
366 cervical disease severity (LGSIL, p=0.002; HGSIL, p=0.001) (S4 Fig. A, S3 Table). High levels
367 of anti-inflammatory cytokines associated with changes in bacterial composition in similar patterns
368 as pro-inflammatory cytokines, with significant differences regardless of HPV infection
369 (NILM/HPV-, p=0.001; NILM/HPV+, p=0.001) and cervical disease severity (LGSIL, p=0.012;
370 HGSIL, p=0.001) (S4 Fig. D, S3 Table). High levels of traffic-associated cytokines significantly
371 altered bacterial composition regardless of cervical disease severity (LGSIL, p=0.012;
372 High_HGSIL, p=0.001) (S4 Fig. G, S3 Table). Alpha diversity significantly increased with
373 cytokine levels for both pro-inflammatory (NILM/HPV-, p=0.035; NILM/HPV+, p=0.002)
374 (LGSIL, p=0.002; HGSIL p=0.001) and anti-inflammatory (NILM/HPV-, p=0.039; NILM/HPV+,

375 p=0.005) (LGSIL, p=0.001; HGSIL, p=3.55E-4) cytokines regardless of HPV infection and
376 cervical disease (S4 Fig. B, 4E). Traffic-associated cytokines did not have significant alpha
377 diversity differences associated with cytokine concentrations (S4 Fig. H, S4 Table). Taxonomic
378 abundance at species level showed that in the 3 cytokine groups, populations of *L. crispatus*
379 decreases as cytokine levels and cervical disease severity increased. Participants with high levels
380 of cytokines and high-grade cervical disease were dominated by *L. iners*, as *L. crispatus* nearly
381 disappears. Additionally, this group of participants were dominated by *Prevotella sp.*, *A. vaginae*
382 and *G. vaginalis*. Simultaneously, *Lachnospiraceae sp.* was detected mainly on participants with
383 High cytokine levels and HGSIL, confirming the dysbiosis typical of *Lactobacillus* depleted
384 communities (S4 Fig. C, 4F and 4I). LefSe analysis (p=0.05 and 1.5 LDA score cutoffs) revealed
385 an increase in *Lactobacillus* when pro-inflammatory and anti-inflammatory cytokines were low
386 (Fig. 6). Low levels of traffic-associated cytokines presented anaerobic bacteria like *Prevotella*
387 and *Atopobium* with higher abundance (Fig. 6). In contrast, with high cytokine levels in pro-
388 inflammatory and anti-inflammatory cytokines, *Atopobium* and *Prevotella* populations decreased.
389 *Pseudomonas* communities also were reduced in association with pro-inflammatory and traffic-
390 associated cytokines (Fig. 6).

391

392 **Fig. 6. Linear discriminant analysis (LDA) effect size (LEfSe) for (A) pro-inflammatory (IL-**
393 **1 β , TNF α , IFN γ , IL-6) (LDA score 1.5), (B) anti-inflammatory (IL-4, IL-10, TGF β 1) (LDA score**
394 **2.25) and (C) traffic (IL-8, MIP1a, MCP1, IP10) (1.5 LDA score) cytokines evaluated considering**
395 **low and high cytokine levels and a p-value cutoff of 0.05.**

396

397

398 Discussion

399 Cervical cancer (CC) is a complex disease where the cervical environment is modified, including
400 cytokine expression that leads to a local immunosuppression state (18). Approximately 15 high-
401 risk HPV strains cause most cervical cancers; however the detection of HPV has a low positive
402 predictive value for invasive cervical cancer, as few HPV+ women progress to High-Grade
403 Squamous Intraepithelial Lesions (HGSIL) (6,37). Inflammation and the microbiome could be the
404 missing link to understanding the actual cellular mechanisms leading to dysplasia and cancer.
405 Indeed, to provide an accurate diagnosis and prognosis of cervical disease progression, screening
406 tests have limited sensitivity for histopathology and cytology (38). Our sensitive HPV genotyping
407 method demonstrated that HPV prevalence in this cohort was 67.0% (encompassing infections
408 with any HPV type) and that co-infections with any HPV serotype were primarily present in low-
409 grade lesions (44.4%) and exclusively high-risk types were more prevalent in HGSIL (82.3%), a
410 prevalence previously reported by our team (11) and Hispanic and Amerindian peoples (39). This
411 higher prevalence exceeds those reported for Costa Ricans (40), or women in Surinam (41),
412 Nigeria (42), Turkey (43) or Italy (44). This can be attributed to the fact that these women are
413 recruited in colposcopy clinics and are therefore not representative of the Puerto Rican population.

414 Modifying the host innate immune system is a well-known feature of numerous malignancies,
415 including HPV-driven cancers (45). HPV interferes with the cytokines, Toll-like receptors (TLRs),
416 and the overall inflammatory process, occurring in the early stages of the immune response
417 (46,47). Together, cytokines and TLRs identify HPV and encourage immunological signalings
418 such as cell development and differentiation (45,47). In cervical HPV infections, an impaired
419 immune response to the virus may lead to cervical disease progression (48). Overall, we found that

420 any HPV infection elevated all cytokine levels but not all cytokines were significant. This suggests
421 that HPV infections alone cannot drive cervical dysplasia progression to cancer (49). Most HR-
422 HPV-infected women do not develop CC because an effective immune response controls the
423 infection and therefore, malignant transformation is halted (50). Additionally, HPV uses several
424 strategies to evade the immune system (Miura et al., 2010), such as reducing the amount of IFN γ ,
425 altering the activation of antiviral and antitumor immune cells such as NK cells and T cells with
426 antiviral and antitumor activity (51). In addition to this, an imbalance of the mucosal microbiome,
427 such as a loss in protective *Lactobacillus* and physicochemical changes, causes alterations of the
428 vaginal mucosa and the cervical epithelium, exercising a pattern of selective pressure on the
429 microbiota (52).

430 Several studies have already established background data on how the microbiome is modified by
431 HPV infections, stating that HPV infections alone are not enough to drive significant changes that
432 translate into epithelial modifications to cancer (11,53). Nonetheless, other studies suggested
433 changes in the composition of the vaginal microbiota associated with human papillomavirus
434 infection (54–56). Our results show greater microbiota diversity and a lower abundance of
435 lactobacilli among HPV-positive women, which is congruent with previous studies (J. E. Lee et
436 al. 2013; Oh et al. 2015; Reimers et al. 2016, Godoy-Vitorino et al. 2018). It is still unclear why
437 some HR-HPV infections clear while others persist, causing dysplasia and even cervical cancer.
438 Therefore, since only persistent HR-HPV infection has been associated with immune response and
439 vaginal dysbiosis, molecular differences between transient and persistent HR-HPV infection may
440 hold information to explain this phenomenon (37).

441 Concerning cervical lesions, we found a strong microbiome association with the cervical
442 phenotype (lesion severity), with a significantly higher diversity value (Shannon) in HGSIL

443 compared to NILM/HPV- and NILM HPV+ participants, but not substantially different from
444 LGSIL. Our findings coincide with most studies suggesting an association between *L. iners* and
445 HGSIL (60,61). *Lactobacillus* produces have several mechanisms that function as a defensive
446 barrier for invasive bacteria, such as, the production of significant amounts of bacteriocins that
447 contributes to colonization the use of available glycogen to produce lactic acid, lowering vaginal
448 pH, responsible of lysing bacteria other than *Lactobacillus* (62–65)(Amir et al. 2020; Cruickshank
449 1934; O’Hanlon et al. 2013; Zhou et al. 2019). The loss of this defensive strategy due to
450 *Lactobacillus* community reduction, explains the increase of *Atopobium vaginae*, *Prevotella* spp.,
451 and *Gardnerella* spp.

452 Our study confirms cervicovaginal microbial dysbiosis in high-risk HPV and cervical disease
453 severity associated with pro-inflammatory cytokines, validating other studies in other cohorts
454 (18,66). IL-1 β and IFN γ were significantly more abundant in high-grade disease participants,
455 associated with a loss in *Lactobacillus* validating previous studies where high concentrations of
456 pro-inflammatory cytokines were detected in women with cervical neoplasia (67–69). The rise
457 in IL-1 β can be attributed to cellular mechanisms such as tumorigenesis, angiogenesis (70) or
458 metastasis (71); as well as increased risk of CC in women with high grade cervical lesions (72)
459 associated with either polymorphism (73), reactive oxygen species (ROS), COX2 or NADPH
460 oxidase (74). We found higher levels of expression of IL-6 associated with high levels of *L. iners*.
461 IL-6 is essential for the growth, metastasis, and initiation of cancer; affecting tumor growth,
462 differentiation, and the host immune defense mechanism (75). Many immune and nonimmune
463 cells, such as T cells, monocytes, macrophages, dendritic cells, and some cancer cells -such as CC
464 cells- produce IL-6 (76,77). IL-6 induces CC growth by vascular endothelial growth factor
465 (VEGF)-dependent angiogenesis (78). In addition, higher expression of IL-6 was shown in

466 cancerous tissues than in adjacent non-cancer tissues in early-stage CC patients, confirming its
467 association to cancer development (79). The less protective Lactobacilli (*L. iners*) may be
468 stimulating the production of these mediators, this could be due in part to their heterogeneous
469 genome, that unlike the protective counterparts, do not produce as much lactic acid or hydrogen
470 peroxide (80). Although the slight increase in IL-10 among LGSIL is not significant, we
471 hypothesize that IL-10 may increase in parallel with the development of intraepithelial lesion as it
472 does in cancer, promoting the expression of HPV oncoproteins (Berti et al. 2017).

473 Taxonomic profiles of cervical microbial communities were sorted into community state types
474 (CSTs), allowing a valuable categorization for statistical modeling and comparisons between
475 datasets (13,14). The vaginal microbiota in this Hispanic women cohort of women living in Puerto
476 Rico was dominated by CST IV-C (57.1%, non-*Lactobacillus* profile) and CST IV-A (24.1%, *G.*
477 *vaginalis* moderate), which confirms previous work of our lab (11), and suggests similarities to
478 other US Hispanics (13) and Venezuelans (81). Even when CST IV-C dominated all three
479 categories of cervical cytology (NILM, LGSIL, HGSIL), but was more predominant in healthy
480 patients (NILM) (62.5%). CST IV-C is characterized by a low relative abundance of *Lactobacillus*
481 *spp.*, *G. vaginalis*, and *A. vaginae*, while instead is characterized by the abundance of a diverse
482 array of facultative and strictly anaerobic bacteria, thus revealing that Hispanic women living in
483 PR are in constant dysbiosis with a microbiome dominated by anaerobic non-lactobacillus
484 communities. Overall, the high prevalence of CST-IV across all samples reflects a cervical
485 microbial environment with low stability and less likelihood to return to its equilibrium state after
486 a perturbation, which increases the risk of developing adverse health outcomes (82,83). In
487 Hispanics living in Puerto Rico, the typical healthy vaginal microbial profile seems to be already
488 diverse. It does not correspond to that of US Caucasians, mostly dominated by CST-I, being more

489 like that of other US Hispanics, which are more prone to vaginal dysbiosis regulation and
490 inflammatory conditions (Ravel et al. 2011). CST-IV represents a highly diverse bacterial profile
491 and has been associated with high pro-inflammatory cytokine levels, which damage the
492 endocervix's columnar epithelial barrier, exposing it to colonization to other microbial or
493 pathogenic agents (12,84).

494 Microbiome analysis revealed that high levels of all three groups of cytokines (anti-inflammatory,
495 pro-inflammatory, and traffic-associated) were related to significant bacterial community
496 composition changes and high diversity levels (Shannon). Low levels of *Sneathia spp.* are
497 associated with higher concentrations of IL-1 β and TNF α , this taxa that is part of the normal
498 microbiota of the genitourinary tracts of men and women is now considered a possible pathogen
499 of the female reproductive tract (85), *Sneathia spp.* are also regarded as good biomarkers for
500 bacterial vaginosis (86), a classical dysbiosis associated with abnormalities in cervical smears (87).
501 Previous studies have described that *Lactobacillus* can prevent the colonization of exogenous
502 pathogens by producing lactic acid, bacteriocins and reactive oxygen species (ROS) (13,88,89).
503 Lactobacilli, promote homeostasis in the cervicovaginal environment and are associated with low
504 levels of pro-inflammatory and anti-inflammatory cytokines. In contrast, low concentrations of
505 traffic-associated-related cytokines are associated with an increase in *Prevotella* and *Atopobium*,
506 suggesting that there is little induction of immune cell tissue migration to combat these bacteria.
507 Previous studies reported that *Atopobium vaginae* could trigger an innate immune response
508 involving IL-6 and IL-8 using an in vitro model of bacterial vaginosis (90), and this could be
509 happening *in vivo*. Also, a study suggested that *Prevotella* may provide nutrients such as ammonia
510 and amino acids to other microbial community members such as
511 *Gardnerella* and *Peptostreptococcus* (91), assuming a metabolic hub for vaginal microbiota and

512 being a key player in vaginal dysbiosis (92). *Prevotella* is therefore critical for maintaining a
513 dysbiotic ecosystem in the cervix.

514 Cervical cancer is a complex multifactorial disease, and further research, including time-series
515 analyses of longitudinal sampling, is needed to improve our understanding of its etiology. Our
516 study evidence that high concentrations of all three cytokine groups (inflammatory, anti-
517 inflammatory, and traffic-associated) were associated with cervical dysbiosis, which occurs
518 through dramatic losses of protective *Lactobacilli* and the presence of diverse anaerobic taxa. The
519 cervical microbiota in Hispanic women living in Puerto Rico is highly diverse and dominated by
520 CSTs III and IV. Further changes of the microbiota with HR-HPV and inflammation reveal that
521 the joint host-microbe interaction analyses via cytokine signaling and microbiota in precancerous
522 lesions have great translational potential.

523

524 Acknowledgments

525 We would like to acknowledge Dr. Robert D. Burk, Dr. Mykhaylo Usyk for kindly providing the
526 curated extended GreenGenes database we cite in the methods section, which integrates the
527 GreenGenes database, the Human Oral Microbiome Database (HOMD) and cervicovaginal
528 microbiome 16S reference sequences retrieved from NCBI. Also, we want to thank Dr. Michael
529 T. France for his help in adapting our taxonomy for the VALENCIA classification. We thank all
530 the medical personnel from the gynecology clinics who participated in the screening program and
531 sample collection and the students who helped with metadata curation. We offer special thanks to
532 the participants for contributing to our study.

533

534 References

- 535 1. Mitchell C. PAHO/WHO | Cervical cancer is the third most common cancer among women in
536 Latin America and the Caribbean, but it can be prevented [Internet]. Pan American Health
537 Organization / World Health Organization. 2019 [cited 2022 May 17]. Available from:
538 [https://www3.paho.org/hq/index.php?option=com_content&view=article&id=14947:cervical](https://www3.paho.org/hq/index.php?option=com_content&view=article&id=14947:cervical-cancer-is-the-third-most-common-cancer-among-women-in-latin-america-and-the-caribbean-but-it-can-be-prevented&Itemid=1926&lang=en)
539 [-cancer-is-the-third-most-common-cancer-among-women-in-latin-america-and-the-](https://www3.paho.org/hq/index.php?option=com_content&view=article&id=14947:cervical-cancer-is-the-third-most-common-cancer-among-women-in-latin-america-and-the-caribbean-but-it-can-be-prevented&Itemid=1926&lang=en)
540 [caribbean-but-it-can-be-prevented&Itemid=1926&lang=en](https://www3.paho.org/hq/index.php?option=com_content&view=article&id=14947:cervical-cancer-is-the-third-most-common-cancer-among-women-in-latin-america-and-the-caribbean-but-it-can-be-prevented&Itemid=1926&lang=en)
- 541 2. Glasgow L, Lewis R, Charles S. The cancer epidemic in the Caribbean region: Further
542 opportunities to reverse the disease trend. *The Lancet Regional Health - Americas*. 2022
543 Sep;13:100295.
- 544 3. Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular
545 biology and disease association. *Rev Med Virol*. 2015 Mar;25 Suppl 1:2–23.
- 546 4. Lehoux M, D’Abramo CM, Archambault J. Molecular mechanisms of human papillomavirus-
547 induced carcinogenesis. *Public Health Genomics*. 2009;12(5–6):268–80.
- 548 5. Pradhan SR, Mahata S, Ghosh D, Sahoo PK, Sarkar S, Pal R, et al. Human Papillomavirus
549 Infections in Pregnant Women and Its Impact on Pregnancy Outcomes: Possible Mechanism
550 of Self-Clearance [Internet]. *Human Papillomavirus*. IntechOpen; 2020 [cited 2022 May 17].
551 Available from: <https://www.intechopen.com/chapters/70423>
- 552 6. Beata S, Dariusz S, Marianna M, Hanna R, Zbigniew K, Luiza W, et al. The Role of Human
553 Papillomavirus in Cervical Cancer. *Int J Cancer Clin Res* [Internet]. 2019 Sep 28 [cited 2022

- 554 May 17];6(5). Available from: [https://www.clinmedjournals.org/articles/ijccr/international-](https://www.clinmedjournals.org/articles/ijccr/international-journal-of-cancer-and-clinical-research-ijccr-6-125.php?jid=ijccr)
555 [journal-of-cancer-and-clinical-research-ijccr-6-125.php?jid=ijccr](https://www.clinmedjournals.org/articles/ijccr/international-journal-of-cancer-and-clinical-research-ijccr-6-125.php?jid=ijccr)
- 556 7. Okunade KS. Human papillomavirus and cervical cancer. *Journal of Obstetrics and*
557 *Gynaecology*. 2020 Jul 3;40(5):602–8.
- 558 8. Conesa-Zamora P, Ortiz-Reina S, Moya-Biosca J, Doménech-Peris A, Orantes-Casado FJ,
559 Pérez-Guillermo M, et al. Genotype distribution of human papillomavirus (HPV) and co-
560 infections in cervical cytologic specimens from two outpatient gynecological clinics in a
561 region of southeast Spain. *BMC Infect Dis*. 2009 Aug 10;9:124.
- 562 9. Norenhag J, Du J, Olovsson M, Verstraelen H, Engstrand L, Brusselaers N. The vaginal
563 microbiota, human papillomavirus and cervical dysplasia: a systematic review and network
564 meta-analysis. *BJOG*. 2020 Jan;127(2):171–80.
- 565 10. Pfeiffer JK. Host response: Microbiota prime antiviral response. *Nat Microbiol*. 2016 Jan
566 27;1:15029.
- 567 11. Godoy-Vitorino F, Romaguera J, Zhao C, Vargas-Robles D, Ortiz-Morales G, Vázquez-
568 Sánchez F, et al. Cervicovaginal Fungi and Bacteria Associated With Cervical Intraepithelial
569 Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population. *Front*
570 *Microbiol*. 2018;9:2533.
- 571 12. Castle PE, Hillier SL, Rabe LK, Hildesheim A, Herrero R, Bratti MC, et al. An association of
572 cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic
573 human papillomavirus (HPV). *Cancer Epidemiol Biomarkers Prev*. 2001 Oct;10(10):1021–7.

- 574 13. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SSK, McCulle SL, et al. Vaginal microbiome
575 of reproductive-age women. *Proc Natl Acad Sci U S A*. 2011 Mar 15;108 Suppl 1:4680–7.
- 576 14. France MT, Ma B, Gajer P, Brown S, Humphrys MS, Holm JB, et al. VALENCIA: a nearest
577 centroid classification method for vaginal microbial communities based on composition.
578 *Microbiome*. 2020 Dec;8(1):166.
- 579 15. Godoy-Vitorino F, Romaguera J, Ortiz Morales G, Vázquez-Sánchez F, Dominicci-Maura A,
580 Ortiz A. *Malassezia globosa* and *Malassezia restricta* are associated with high-risk HPV
581 infections in the anogenital tract. *Journal of Lower Genital Tract Disease*. 2019 Apr
582 4;22:PMID: 30889031.
- 583 16. Chorna N, Romaguera J, Godoy-Vitorino F. Cervicovaginal Microbiome and Urine
584 Metabolome Paired Analysis Reveals Niche Partitioning of the Microbiota in Patients with
585 Human Papilloma Virus Infections. *Metabolites*. 2020 Jan 15;10(1):36.
- 586 17. Ilhan ZE, Łaniewski P, Thomas N, Roe DJ, Chase DM, Herbst-Kralovetz MM. Deciphering
587 the complex interplay between microbiota, HPV, inflammation and cancer through
588 cervicovaginal metabolic profiling. *EBioMedicine*. 2019 Jun;44:675–90.
- 589 18. Audirac-Chalifour A, Torres-Poveda K, Bahena-Román M, Téllez-Sosa J, Martínez-
590 Barnette J, Cortina-Ceballos B, et al. Cervical Microbiome and Cytokine Profile at Various
591 Stages of Cervical Cancer: A Pilot Study. *PLoS One*. 2016;11(4):e0153274.
- 592 19. Güzel C, Govorukhina NI, Wisman GBA, Stingl C, Dekker LJM, Klip HG, et al. Proteomic
593 alterations in early stage cervical cancer. *Oncotarget*. 2018 Apr 6;9(26):18128–47.

- 594 20. Olivier J, Johnson WD, Marshall GD. The logarithmic transformation and the geometric mean
595 in reporting experimental IgE results: what are they and when and why to use them? *Ann*
596 *Allergy Asthma Immunol.* 2008 Apr;100(4):333–7.
- 597 21. Moscicki AB, Shi B, Huang H, Barnard E, Li H. Cervical-Vaginal Microbiome and Associated
598 Cytokine Profiles in a Prospective Study of HPV 16 Acquisition, Persistence, and Clearance.
599 *Frontiers in Cellular and Infection Microbiology* [Internet]. 2020 [cited 2022 May 16];10.
600 Available from: <https://www.frontiersin.org/article/10.3389/fcimb.2020.569022>
- 601 22. Scott ME, Shvetsov YB, Thompson PJ, Hernandez BY, Zhu X, Wilkens LR, et al. Cervical
602 cytokines and clearance of incident human papillomavirus infection: Hawaii HPV cohort
603 study: Mucosal cytokines and cervical HPV clearance. *Int J Cancer.* 2013 Sep 1;133(5):1187–
604 96.
- 605 23. Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Huntley J, Fierer N, et al. Ultra-high-
606 throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. *ISME*
607 *J.* 2012 Aug;6(8):1621–4.
- 608 24. Gonzalez A, Navas-Molina JA, Kosciolk T, McDonald D, Vázquez-Baeza Y, Ackermann G,
609 et al. Qiita: rapid, web-enabled microbiome meta-analysis. *Nat Methods.* 2018
610 Oct;15(10):796–8.
- 611 25. Amir A, McDonald D, Navas-Molina JA, Kopylova E, Morton JT, Zech Xu Z, et al. Deblur
612 Rapidly Resolves Single-Nucleotide Community Sequence Patterns. Gilbert JA, editor.
613 *mSystems* [Internet]. 2017 Apr 21 [cited 2022 Feb 24];2(2). Available from:
614 <https://journals.asm.org/doi/10.1128/mSystems.00191-16>

- 615 26. Usyk M, Zolnik CP, Castle PE, Porras C, Herrero R, Gradissimo A, et al. Cervicovaginal
616 microbiome and natural history of HPV in a longitudinal study. Silvestri G, editor. PLoS
617 Pathog. 2020 Mar 26;16(3):e1008376.
- 618 27. DeSantis TZ, Hugenholtz P, Larsen N, Rojas M, Brodie EL, Keller K, et al. Greengenes, a
619 Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB. Appl
620 Environ Microbiol. 2006 Jul;72(7):5069–72.
- 621 28. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al.
622 Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2.
623 Nat Biotechnol. 2019 Aug;37(8):852–7.
- 624 29. Bray JR, Curtis JT. An Ordination of the Upland Forest Communities of Southern Wisconsin.
625 Ecological Monographs. 1957 Oct;27(4):325–49.
- 626 30. Shannon CE. A Mathematical Theory of Communication. Bell System Technical Journal.
627 1948 Jul;27(3):379–423.
- 628 31. McMurdie PJ, Holmes S. phyloseq: An R Package for Reproducible Interactive Analysis and
629 Graphics of Microbiome Census Data. PLOS ONE. 2013 Apr 22;8(4):e61217.
- 630 32. Hadley W. Ggplot2. New York, NY: Springer Science+Business Media, LLC; 2016.
- 631 33. Oksanen J, Simpson GL, Blanchet FG, Kindt R, Legendre P, Minchin PR, et al. vegan:
632 Community Ecology Package [Internet]. 2022 [cited 2022 May 16]. Available from:
633 <https://CRAN.R-project.org/package=vegan>

- 634 34. Anderson MJ. Permutation tests for univariate or multivariate analysis of variance and
635 regression. *Can J Fish Aquat Sci.* 2001 Mar 1;58(3):626–39.
- 636 35. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al. Metagenomic
637 biomarker discovery and explanation. *Genome Biol.* 2011;12(6):R60.
- 638 36. Chong J, Liu P, Zhou G, Xia J. Using MicrobiomeAnalyst for comprehensive statistical,
639 functional, and meta-analysis of microbiome data. *Nat Protoc.* 2020 Mar;15(3):799–821.
- 640 37. B Q, Z J, Q S, C J, Z L, X M. Cervicovaginal microbiota dysbiosis correlates with HPV
641 persistent infection. *Microbial pathogenesis* [Internet]. 2021 Mar [cited 2022 Sep 15];152.
642 Available from: <https://pubmed.ncbi.nlm.nih.gov/33207260/>
- 643 38. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American
644 Cancer Society, American Society for Colposcopy and Cervical Pathology, and American
645 Society for Clinical Pathology screening guidelines for the prevention and early detection of
646 cervical cancer. *CA Cancer J Clin.* 2012 Jun;62(3):147–72.
- 647 39. Vargas-Robles D, Magris M, Morales N, de Koning MNC, Rodríguez I, Nieves T, et al. High
648 Rate of Infection by Only Oncogenic Human Papillomavirus in Amerindians. *mSphere.* 2018
649 Jun 27;3(3):e00176-18.
- 650 40. Castro FA, Quint W, Gonzalez P, Katki HA, Herrero R, van Doorn LJ, et al. Prevalence of and
651 risk factors for anal human papillomavirus infection among young healthy women in Costa
652 Rica. *J Infect Dis.* 2012 Oct 1;206(7):1103–10.

- 653 41. Geraets DT, Grünberg AW, van der Helm JJ, Schim van der Loeff MF, Quint KD, Sabajo
654 LOA, et al. Cross-sectional study of genital carcinogenic HPV infections in Paramaribo,
655 Suriname: prevalence and determinants in an ethnically diverse population of women in a pre-
656 vaccination era. *Sex Transm Infect.* 2014 Dec;90(8):627–33.
- 657 42. Adebamowo SN, Ma B, Zella D, Famooto A, Ravel J, Adebamowo C. *Mycoplasma hominis*
658 and *Mycoplasma genitalium* in the Vaginal Microbiota and Persistent High-Risk Human
659 Papillomavirus Infection. *Front Public Health.* 2017 Jun 26;5:140.
- 660 43. Barut MU, Yildirim E, Kahraman M, Bozkurt M, Imirzalioglu N, Kubar A, et al. Human
661 Papilloma Viruses and Their Genotype Distribution in Women with High Socioeconomic
662 Status in Central Anatolia, Turkey: A Pilot Study. *Med Sci Monit.* 2018 Jan 4;24:58–66.
- 663 44. Carozzi F, Puliti D, Ocello C, Anastasio PS, Moliterni EA, Perinetti E, et al. Monitoring
664 vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in
665 the Basilicata region, Italy. *BMC Infect Dis.* 2018 Jan 15;18:38.
- 666 45. Grabowska AK, Riemer AB. The invisible enemy - how human papillomaviruses avoid
667 recognition and clearance by the host immune system. *Open Virol J.* 2012;6:249–56.
- 668 46. Basith S, Manavalan B, Yoo TH, Kim SG, Choi S. Roles of toll-like receptors in cancer: a
669 double-edged sword for defense and offense. *Arch Pharm Res.* 2012 Aug;35(8):1297–316.
- 670 47. Turner MD, Nedjai B, Hurst T, Pennington DJ. Cytokines and chemokines: At the crossroads
671 of cell signalling and inflammatory disease. *Biochim Biophys Acta.* 2014
672 Nov;1843(11):2563–82.

- 673 48. Barros MR, de Oliveira THA, de Melo CML, Venuti A, de Freitas AC. Viral Modulation of
674 TLRs and Cytokines and the Related Immunotherapies for HPV-Associated Cancers. *J*
675 *Immunol Res.* 2018 May 2;2018:2912671.
- 676 49. Hu Z, Ma D. The precision prevention and therapy of HPV-related cervical cancer: new
677 concepts and clinical implications. *Cancer Med.* 2018 Oct;7(10):5217–36.
- 678 50. Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, et al. Incident
679 cervical HPV infections in young women: transition probabilities for CIN and infection
680 clearance. *Cancer Epidemiol Biomarkers Prev.* 2011 Feb;20(2):287–96.
- 681 51. Sasagawa T, Takagi H, Makinoda S. Immune responses against human papillomavirus (HPV)
682 infection and evasion of host defense in cervical cancer. *J Infect Chemother.* 2012
683 Dec;18(6):807–15.
- 684 52. Kim TK, Thomas SM, Ho M, Sharma S, Reich CI, Frank JA, et al. Heterogeneity of vaginal
685 microbial communities within individuals. *J Clin Microbiol.* 2009 Apr;47(4):1181–9.
- 686 53. Bienkowska-Haba M, Luszczek W, Myers JE, Keiffer TR, DiGiuseppe S, Polk P, et al. A new
687 cell culture model to genetically dissect the complete human papillomavirus life cycle. *PLOS*
688 *Pathogens.* 2018 Mar 1;14(3):e1006846.
- 689 54. Tamarelle J, Thiébaud ACM, de Barbeyrac B, Bébéar C, Ravel J, Delarocque-Astagneau E.
690 The vaginal microbiota and its association with human papillomavirus, Chlamydia
691 trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium infections: a systematic
692 review and meta-analysis. *Clin Microbiol Infect.* 2019 Jan;25(1):35–47.

- 693 55. Gillet E, Meys JFA, Verstraelen H, Verhelst R, De Sutter P, Temmerman M, et al. Association
694 between Bacterial Vaginosis and Cervical Intraepithelial Neoplasia: Systematic Review and
695 Meta-Analysis. *PLoS One*. 2012 Oct 2;7(10):e45201.
- 696 56. Brusselaers N, Shrestha S, van de Wijgert J, Verstraelen H. Vaginal dysbiosis and the risk of
697 human papillomavirus and cervical cancer: systematic review and meta-analysis. *Am J Obstet*
698 *Gynecol*. 2019 Jul;221(1):9-18.e8.
- 699 57. Lee JE, Lee S, Lee H, Song YM, Lee K, Han MJ, et al. Association of the vaginal microbiota
700 with human papillomavirus infection in a Korean twin cohort. *PLoS One*. 2013;8(5):e63514.
- 701 58. Oh HY, Kim BS, Seo SS, Kong JS, Lee JK, Park SY, et al. The association of uterine cervical
702 microbiota with an increased risk for cervical intraepithelial neoplasia in Korea. *Clin*
703 *Microbiol Infect*. 2015 Jul;21(7):674.e1-9.
- 704 59. Reimers LL, Mehta SD, Massad LS, Burk RD, Xie X, Ravel J, et al. The Cervicovaginal
705 Microbiota and Its Associations With Human Papillomavirus Detection in HIV-Infected and
706 HIV-Uninfected Women. *J Infect Dis*. 2016 Nov 1;214(9):1361–9.
- 707 60. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular Identification of Bacteria Associated with
708 Bacterial Vaginosis. *N Engl J Med*. 2005 Nov 3;353(18):1899–911.
- 709 61. Cancer Facts & Figures for Hispanic/Latino People 2021-2023. :40.
- 710 62. Amir M, Brown JA, Rager SL, Sanidad KZ, Ananthanarayanan A, Zeng MY. Maternal
711 Microbiome and Infections in Pregnancy. *Microorganisms*. 2020 Dec 15;8(12):E1996.

- 712 63. O'Hanlon DE, Moench TR, Cone RA. Vaginal pH and microbicidal lactic acid when
713 lactobacilli dominate the microbiota. *PLoS One*. 2013;8(11):e80074.
- 714 64. Cruickshank R. The conversion of the glycogen of the vagina into lactic acid. *The Journal of*
715 *Pathology and Bacteriology*. 1934;39(1):213–9.
- 716 65. Zhou Y, Wang L, Pei F, Ji M, Zhang F, Sun Y, et al. Patients With LR-HPV Infection Have a
717 Distinct Vaginal Microbiota in Comparison With Healthy Controls. *Front Cell Infect*
718 *Microbiol*. 2019;9:294.
- 719 66. Łaniewski P, Barnes D, Goulder A, Cui H, Roe DJ, Chase DM, et al. Linking cervicovaginal
720 immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-
721 Hispanic and Hispanic women. *Sci Rep*. 2018 Dec;8(1):7593.
- 722 67. Campisciano G, Zanotta N, Licastro D, De Seta F, Comar M. In vivo microbiome and
723 associated immune markers: New insights into the pathogenesis of vaginal dysbiosis. *Sci Rep*.
724 2018 Feb 2;8(1):2307.
- 725 68. De Seta F, Campisciano G, Zanotta N, Ricci G, Comar M. The Vaginal Community State
726 Types Microbiome-Immune Network as Key Factor for Bacterial Vaginosis and Aerobic
727 Vaginitis. *Front Microbiol*. 2019;10:2451.
- 728 69. Torcia MG. Interplay among Vaginal Microbiome, Immune Response and Sexually
729 Transmitted Viral Infections. *Int J Mol Sci*. 2019 Jan 11;20(2):E266.

- 730 70. Filippi I, Carraro F, Naldini A. Interleukin-1 β Affects MDAMB231 Breast Cancer Cell
731 Migration under Hypoxia: Role of HIF-1 α and NF κ B Transcription Factors. *Mediators*
732 *Inflamm.* 2015;2015:789414.
- 733 71. Apte RN, Voronov E. Is interleukin-1 a good or bad “guy” in tumor immunobiology and
734 immunotherapy? *Immunol Rev.* 2008 Apr;222:222–41.
- 735 72. Iwata T, Fujii T, Morii K, Saito M, Sugiyama J, Nishio H, et al. Cytokine profile in cervical
736 mucosa of Japanese patients with cervical intraepithelial neoplasia. *Int J Clin Oncol.* 2015
737 Feb;20(1):126–33.
- 738 73. Qian N, Chen X, Han S, Qiang F, Jin G, Zhou X, et al. Circulating IL-1beta levels,
739 polymorphisms of IL-1B, and risk of cervical cancer in Chinese women. *J Cancer Res Clin*
740 *Oncol.* 2010 May;136(5):709–16.
- 741 74. Arima K, Komohara Y, Bu L, Tsukamoto M, Itoyama R, Miyake K, et al. Downregulation of
742 15-hydroxyprostaglandin dehydrogenase by interleukin-1 β from activated macrophages leads
743 to poor prognosis in pancreatic cancer. *Cancer Sci.* 2018 Feb;109(2):462–70.
- 744 75. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for
745 cancer. *Cancer Treat Rev.* 2012 Nov;38(7):904–10.
- 746 76. Pahne-Zeppenfeld J, Schröer N, Walch-Rückheim B, Oldak M, Gorter A, Hegde S, et al.
747 Cervical cancer cell-derived interleukin-6 impairs CCR7-dependent migration of MMP-9-
748 expressing dendritic cells. *International Journal of Cancer.* 2014;134(9):2061–73.

- 749 77. Suradej B, Sookkhee S, Panyakaew J, Mungkornasawakul P, Wikan N, Smith DR, et al.
750 *Kaempferia parviflora* Extract Inhibits STAT3 Activation and Interleukin-6 Production in
751 HeLa Cervical Cancer Cells. *International Journal of Molecular Sciences*. 2019
752 Jan;20(17):4226.
- 753 78. Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, et al. Interleukin-6 promotes cervical
754 tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. *Oncogene*. 2003
755 Mar;22(10):1517–27.
- 756 79. Wei LH, Kuo ML, Chen CA, Cheng WF, Cheng SP, Hsieh FJ, et al. Interleukin-6 in cervical
757 cancer: the relationship with vascular endothelial growth factor. *Gynecol Oncol*. 2001
758 Jul;82(1):49–56.
- 759 80. Choi HS, Kim KM, Kim CH, Kim SM, Oh JS. Hydrogen Peroxide Producing Lactobacilli in
760 Women with Cervical Neoplasia. *Cancer Res Treat*. 2006 Apr;38(2):108–11.
- 761 81. Vargas-Robles D, Morales N, Rodríguez I, Nieves T, Godoy-Vitorino F, Alcaraz LD, et al.
762 Changes in the vaginal microbiota across a gradient of urbanization. *Sci Rep*. 2020
763 Dec;10(1):12487.
- 764 82. Eastment MC, McClelland RS. Vaginal microbiota and susceptibility to HIV. *AIDS*. 2018 Mar
765 27;32(6):687–98.
- 766 83. Chen Y, Qiu X, Wang W, Li D, Wu A, Hong Z, et al. Human papillomavirus infection and
767 cervical intraepithelial neoplasia progression are associated with increased vaginal
768 microbiome diversity in a Chinese cohort. *BMC Infect Dis*. 2020 Aug 26;20(1):629.

- 769 84. Anahtar MN, Byrne EH, Doherty KE, Bowman BA, Yamamoto HS, Soumillon M, et al.
770 Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female
771 genital tract. *Immunity*. 2015 May 19;42(5):965–76.
- 772 85. Harwich MD, Serrano MG, Fettweis JM, Alves JMP, Reimers MA, Vaginal Microbiome
773 Consortium (additional members), et al. Genomic sequence analysis and characterization of
774 *Sneathia amnii* sp. nov. *BMC Genomics*. 2012;13 Suppl 8:S4.
- 775 86. Shipitsyna E, Roos A, Datcu R, Hallén A, Fredlund H, Jensen JS, et al. Composition of the
776 vaginal microbiota in women of reproductive age--sensitive and specific molecular diagnosis
777 of bacterial vaginosis is possible? *PLoS One*. 2013;8(4):e60670.
- 778 87. Caixeta RCA, Ribeiro AA, Segatti KD, Saddi VA, Fig.ueiredo Alves RR, dos Santos Carneiro
779 MA, et al. Association between the human papillomavirus, bacterial vaginosis and cervicitis
780 and the detection of abnormalities in cervical smears from teenage girls and young women.
781 *Diagn Cytopathol*. 2015 Oct;43(10):780–5.
- 782 88. Boskey ER, Cone RA, Whaley KJ, Moench TR. Origins of vaginal acidity: high D/L lactate
783 ratio is consistent with bacteria being the primary source. *Hum Reprod*. 2001 Sep;16(9):1809–
784 13.
- 785 89. Kroon SJ, Ravel J, Huston WM. Cervicovaginal microbiota, women's health, and reproductive
786 outcomes. *Fertil Steril*. 2018 Aug;110(3):327–36.
- 787 90. Libby EK, Pascal KE, Mordechai E, Adelson ME, Trama JP. *Atopobium vaginae* triggers an
788 innate immune response in an in vitro model of bacterial vaginosis. *Microbes Infect*. 2008
789 Apr;10(4):439–46.

790 91. Vyshenska D, Lam KC, Shulzhenko N, Morgun A. Interplay between viruses and bacterial
791 microbiota in cancer development. *Semin Immunol.* 2017 Aug;32:14–24.

792 92. Si J, You HJ, Yu J, Sung J, Ko G. Prevotella as a Hub for Vaginal Microbiota under the
793 Influence of Host Genetics and Their Association with Obesity. *Cell Host Microbe.* 2017 Jan
794 11;21(1):97–105.

795

796 Supporting information

797 **S1 Fig. CST prevalence distribution among cytokine levels and groups.** CSTs according to
798 category groups were used to compute Fisher’s test using pairwise analysis to compare between
799 groups. Results were depicted in boxplots for cervical disease. Significant differences are
800 highlighted by brackets and corresponding p-values.

801

802 **S2 Fig. Cytokine Profiles** of (A) pro inflammatory (IL-1 β , TNF α , IFN γ , IL-6), (B) anti-
803 inflammatory (IL-4, IL-10, TGF β 1) and (C) traffic (IL-8, MIP1a, MCP1, IP10) cytokines
804 evaluated through LUMINEX, plotted according to HPV risk. Fluorescence Intensity values were
805 used to compute multiple comparison analysis using ordinary one-way ANOVA with Tukey’s
806 multiple comparisons test. Results were depicted in boxplots for cervical disease. Significant
807 differences are highlighted by brackets and corresponding p-values.

808

809 **S3 Fig. Diversity and cytokine profile analyses comparing samples, according to menopause**
810 **status.** Beta and alpha diversity analyses are represented by non-metric multidimensional scaling

811 (NMDS) (A) and Shannon index boxplots (B). Relative abundance of bacteria at the species level
812 is shown in a relative abundance bar plot (C). Cytokine Profiles of pro inflammatory (D), anti-
813 inflammatory (E) and traffic (F) cytokines, plotted according to HPV risk. Fluorescence Intensity
814 values were used to compute multiple comparison analysis using ordinary one-way ANOVA with
815 Tukey's multiple comparisons test. Significant differences are highlighted by brackets and
816 corresponding p-values.

817

818 **S4 Fig. Diversity analyses comparing samples, according to inflammatory (IL-1 β , TNFa,**
819 **IFNg, IL-6), anti-inflammatory (IL-4, IL-10, TGF β 1), and trafficking (IL-8, MIP1a, MCP1,**
820 **IP10) cytokines.** Bray-Curtis analysis represented by Non-metric multidimensional scaling
821 (NMDS) using pro inflammatory (A), anti-inflammatory (D) and trafficking cytokines (G) as
822 metadata categories. Alpha diversity (Shannon) was calculated and depicted in Figures B, E and
823 H. Bar Plots showing relative abundance of bacteria at the species level for cytokine groups (C, F,
824 I).

825

826 **S1 Table. Study population characteristics (n=91) described by cervical disease status,**
827 **including HPV risk, community state types, and cytokine ranks.**

828

829 **S2 Table. Pairwise comparisons using Pairwise comparison of proportions (Fisher) of the**
830 **cytokine levels. P values were adjusted using Bonferroni corrections.**


831

832 **S3 Table. Non-parametric analyses using ranked beta diversity distances between different**
833 **group depths found in the mapping file, based on the Bray-Curtis table.**

834


835 **S4 Table. Non-parametric t-test comparing observed richness between the different**
836 **metadata categories**

L. crispatus




medRxiv preprint doi: <https://doi.org/10.1101/2023.04.06.23288256>; this version posted April 7, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).


L. iners




Sneathia




Gardnerella



Atopobium



Prevotella




 Very Low

 Low


 High

Figure 5

A.



B.



C.




Figure 1




Figure 3




Figure 4






Figure 2


Pro Inflammatory



Anti Inflammatory



Traffic



Low Cytokine Levels

High Cytokine Levels

Figure 6